Comparative estimation of efficiency of pharmacotherapy of intrauterine growth retardation syndrome
The study has included 210 pregnant women with the intrauterine growth retardation (IUGR) during 27-36 weeks of pregnancy. The control group was composed of 140 patients who underwent a standard therapy by antiaggregants (trental, curantil), non-steroid anabolic agents (kalii orotas, riboxin) and vitamins. Seventy pregnant women constituting the comparison group underwent two courses of treatment by carnitine hydrochloride (n = 36) and Actovegin (n = 34) along with the standard therapy. The survey of the postnatal period showed that application of carnitine hydrochloride alongside the standard therapy for the IUGR syndrome is highly effective. Including Actovegin into the overall IUGR syndrome therapy allows to reduce significantly the frequency of CNS hypoxic-ischemic lesions. The efficacy of the IURG syndrome therapy has been proved to be higher with treatment starting prior to the 32-d week of pregnancy.